Clinical Trials Arena· GlobalData Healthcare·· 1 天前AI 评分22
ESMO26：84 亿美元双特异性 ADC 使 HR+/HER2- 乳腺癌 PFS 翻倍
ESMO26: An $8.4bn bispecific ADC doubles PFS in HR+/HER2- breast cancer
AI 导读
ESMO26 会议上公布，一款价值 84 亿美元的双特异性 ADC 在 HR+/HER2- 乳腺癌中使 PFS 翻倍。该结果来自 Clinical Trials Arena 的报道，具体药物名称、PFS 数值及试验细节未在可见正文中披露。
正文 · 原文
Unlock FREE Access to Premium Content
Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation.
With a free Clinical Trials Arena profile, you can:
- Access exclusive analyst commentary and expert insights
- View premium forecasts and data-driven clinical trial intelligence
- Stay up to date with clinical trial news, regulatory updates, and industry trends
- Receive alerts when new premium content is published
Unlock free access
Already have an account? Login here
Powered by
来源：Clinical Trials Arena · clinicaltrialsarena.com